1067230-65-2

Basic information

• Product Name: 3(R)-BROMOMETHYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 3(R)-BROMOMETHYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;(R)-3-BROMOMETHYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;(R)-N-BOC-3-BROMOMETHYLPYRROLIDINE;(3R)-3-(Bromomethyl)-1-pyrrolidinecarboxylic acid tert-butyl ester;(R)-Tert-butyl 3-(bromomethyl)pyrrolidine-1-carboxylate;(R)-1-Boc-3-(broMoMethyl)pyrrolidine;tert-butyl (3R)-3-(broMoMethyl)pyrrolidine-1-carboxylate;1-Pyrrolidinecarboxylic acid, 3-(bromomethyl)-, 1,1-dimethylethyl ester, (3R)-
• CAS NO: 1067230-65-2
• Molecular Formula: C₁₀H₁₈BrNO₂
• Molecular Weight: 264.16
• Mol File: 1067230-65-2.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 300.1±15.0 °C(Predicted)
• Appearance: /
• Density: 1.312
• Storage Temp.: 2-8°C
• PKA: -2.14±0.40(Predicted)
• CAS DataBase Reference: 3(R)-BROMOMETHYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3(R)-BROMOMETHYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(1067230-65-2)
• EPA Substance Registry System: 3(R)-BROMOMETHYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(1067230-65-2)

Safety Data

• Hazardous Substances Data: 1067230-65-2(Hazardous Substances Data)

Usage

General Description

3(R)-Bromomethyl-pyrrolidine-1-carboxylic acid tert-butyl ester is a chemical compound that is commonly used in the pharmaceutical and research industries. It is a tert-butyl ester derivative of 3(R)-bromomethylpyrrolidine-1-carboxylic acid, which is an important intermediate in the synthesis of various pharmaceutical compounds. 3(R)-BROMOMETHYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is known for its use as a building block in the synthesis of pharmaceuticals, such as antiviral and antifungal agents. It has also been studied for its potential use in the development of new drug therapies. Additionally, it has been utilized in some research applications related to organic synthesis and drug discovery. Overall, this chemical is valuable for its role in the development and production of pharmaceutical compounds and its potential for further research and application in the pharmaceutical and chemical industries.

Upstream product

• 177947-76-1 (3R)-1-(tert-butoxycarbonyl)-3-[(methane-sulfonyloxy)methyl]pyrrolidine 
• 138108-72-2 tert-butyl (R)-3-hydroxymethylpyrrolidine-1-carboxylate 

Downstream Products

• 1433607-45-4 (3R)-N-Boc-3-(((((E)-2-amino-7-(4-fluoro-2-(pyridin-3-yl)phenyl)-4-methyl-7,8-dihydro-6H-quinazolin-5ylidene)amino)oxy)methyl)pyrrolidine 
• 1579514-47-8 (S)-methyl 2-(4-bromophenyl)-3-((1-(tert-butoxycarbonyl)pyrrolidin-3-yl)methyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-1-ene-8-carboxylate 
• 1579511-80-0 (S)-tert-butyl 3-((2-(4-bromophenyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)pyrrolidine-1-carboxylate 

Relevant articles and documents

Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC

Described as a Btk inhibitor, ibrutinib also potently inhibits Bmx and EGFR, two good targets for lung cancer. Owing to its high CLogP (4.07) and low aqueous solubility (a potent anti-cancer agent B6, with beneficial physicochemical parameters (CLogP = 2.56, solubility in water ≈ 0.1 mg/ml) meeting the principles of oral drugs. B6 exhibited anti-proliferation activities against EGFR-expressing cells, especially the mutant ones, such as H1975 (L858R/T790M, IC50 = 0.92 ± 0.19 μM) and HCC827 (Del119 IC50 = 0.014 ± 0.01 μM). Moreover, B6 significantly slowed down H1975 tumor growth with anti-tumor rate of 73.9% (p 50 = 35.7 ± 0.1 nM) over other kinases. So, as a potent Bmx inhibitor, B6 has the potential to be an efficacious treatment for NSCLC with acquired drug resistance.